2320 - 2602
TL;DR
It is concluded that blockchain should be treated as a selective governance and assurance layer rather than a universal database and adoption should proceed through clinically bounded pilots, privacy-by-design architectures, explicit consortium governance, interoperability standards, and evaluation against non-blockchain alternatives.
Abstract
Blockchain technology has moved beyond cryptocurrency to become a proposed trust infrastructure for data-intensive sectors. Healthcare and telemedicine are prominent candidates because care increasingly depends on cross-organizational exchange of sensitive records, remote monitoring streams, digital identity, pharmaceutical traceability, and verifiable clinical research. This paper examines how blockchain may address these needs while critically assessing the barriers that separate technical promise from sustainable clinical adoption. A descriptive-analytical methodology is applied to a bounded body of literature supplied for the study. The sources are systematically read, categorized, compared, and synthesized across four analytical domains: technological foundations, healthcare and telemedicine applications, adoption benefits, and implementation challenges. The analysis finds that blockchain's principal value is not unrestricted on-chain storage, but the creation of tamper-evident transaction histories, programmable access rules, decentralized identity, provenance, and accountable inter-organizational coordination. High-potential applications include patient-mediated electronic health-record exchange, secure teleconsultation transactions, remote monitoring, clinical-trial integrity, pharmaceutical supply-chain traceability, and research data governance. Permissioned networks, smart contracts, standards-based interfaces, and off-chain storage emerge as the most practical architectural pattern. Nevertheless, scalability, interoperability, privacy and erasure rights, governance, legal responsibility, implementation cost, usability, and limited real-world evidence remain substantial barriers. The paper concludes that blockchain should be treated as a selective governance and assurance layer rather than a universal database. Adoption should proceed through clinically bounded pilots, privacy-by-design architectures, explicit consortium governance, interoperability standards, and evaluation against non-blockchain alternatives. Future research should prioritize longitudinal clinical deployments, comparative cost-effectiveness, patient-centered consent, and regulatory accountability.